50916-56-8

Basic information

• Product Name: 3-(2-aminoacetyl)benzonitrile hydrochloride
• Synonyms: 3-(2-aminoacetyl)benzonitrile hydrochloride;3-(2-aminoacetyl)benzonitrile
• CAS NO: 50916-56-8
• Molecular Formula: C9H9ClN2O
• Molecular Weight: 196.63356
• Mol File: 50916-56-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(2-aminoacetyl)benzonitrile hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-aminoacetyl)benzonitrile hydrochloride(50916-56-8)
• EPA Substance Registry System: 3-(2-aminoacetyl)benzonitrile hydrochloride(50916-56-8)

Safety Data

• Hazardous Substances Data: 50916-56-8(Hazardous Substances Data)

Upstream product

• 50916-55-7 3-(2-bromoacetyl)benzonitrile 
• 6136-68-1 3-acethylbenzonitrile 

Downstream Products

• 668972-77-8 ethyl 2-((2-(3-cyanophenyl)-2-oxoethyl)amino)-2-oxoacetate 

Relevant articles and documents

Synthesis, characterization, and biological evaluation of new derivatives targeting MbtI as antitubercular agents

Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most dangerous infectious diseases worldwide. Because several pathogenic strains of Mycobacterium tuberculosis (Mtb) have developed resistance against most of the established anti-TB drugs, new therapeutic options are urgently needed. An attractive target for the development of new antitubercular agents is the salicylate synthase MbtI, an essential enzyme for the mycobacterial siderophore biochemical machinery, absent in human cells. A set of analogues of I and II, two of the most potent MbtI inhibitors identified to date, was synthesized, characterized, and tested to elucidate the structural requirements for achieving an efficient MbtI inhibition and a potent antitubercular activity with this class of compounds. The structure-activity relationships (SAR) here discussed evidenced the importance of the furan as part of the pharmacophore and led to the preparation of six new compounds (IV-IX), which gave us the opportunity to examine a hitherto unexplored position of the phenyl ring. Among them emerged 5-(3-cyano-5-(trifluoromethyl)phenyl)furan-2-carboxylic acid (IV), endowed with comparable inhibitory properties to the previous leads, but a better antitubercular activity, which is a key issue in MbtI inhibitor research. Therefore, compound IV offers promising prospects for future studies on the development of novel agents against mycobacterial infections.

P70 S6 KINASE INHIBITORS

The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.

Thiadizines

Novel heterocyclic compounds of the formula: STR1 wherein either X is --CR1 R2 -- and Y is oxygen, sulphur or --NR3, wherein R1, R2 and R3, which may be the same or different, each is hydrogen or alkyl of up to 4 carbon atoms; or X is oxygen, sulphur or --NH-- and Y is --CH2 --; wherein R4 and R5, which may be the same or different, each is hydrogen, cyano, nitro, amino or hydroxy, or alkylthio of up to 4 carbon atoms, or has various other meanings defined in claim 1, provided that R4 and R5 are not both hydrogen; or wherein R4 and R5 are joined together such that with the benzene ring A they form a benzheterocyclic ring as defined in claim 1; and therein the benzene ring A may optionally bear one or more further substituents; or a salt thereof where appropriate. These compounds possess cardiotonic properties, and some of them possess peripheral vasodilator properties, and they are useful for the treatment of acute or chronic heart failure. Representative of the compounds is N,N-dimethyl-p-(5,6-dihydro-5-oxo-4H-1,3,4-thiadiazin-2-yl)benzamide. Also disclosed are processes for the manufacture of the compounds and pharmaceutical compositions containing them.